Screener
ANI Pharmaceuticals ANIP Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest expense, net | (3,636) | (5,438) | (7,405) | (10,922) |
| Other (expense) income, net | (468) | 1,739 | (1,119) | 1,937 |
| Income Before Income Tax Expense | 37,097 | 10,525 | 77,318 | 30,512 |
| Income tax expense | 12,386 | 1,976 | 23,115 | 6,282 |
| Net Income | $24,711 | $8,549 | $54,203 | $24,230 |
| Dividends on Series A Convertible Preferred Stock | — | (407) | — | (813) |
| Net Income Available to Common Shareholders | $24,711 | $8,142 | $54,203 | $23,417 |
| Basic and Diluted Income Per Share: |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's income tax?
- ANI Pharmaceuticals (ANIP) reported income tax of $12.39M in Q2 2026.
- How has ANI Pharmaceuticals's income tax changed year-over-year?
- ANI Pharmaceuticals's income tax increased by 526.8% year-over-year, from $1.98M to $12.39M.
- What is the long-term trend for ANI Pharmaceuticals's income tax?
- Over 3 years (2021 to 2025), ANI Pharmaceuticals's income tax has grown at a 9.1% compound annual growth rate (CAGR), from -$13.46M to $17.45M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about ANI Pharmaceuticals's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude